Ornidazole - CAS 16773-42-5
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Ornidazole is a 5-nitroimidazole derivative with antiprotozoal and antibacterial properties against anaerobic bacteria.
Publictions citing BOC Sciences Products
  • >> More
Ro7-0207, NSC 95075
1. Inner reorganization limiting electron transfer controlled hydrogen bonding: intra- vs. intermolecular effects
Eduardo Martınez-Gonzalez and Carlos Frontana*. Phys. Chem. Chem. Phys., 2014, 16, 8044—8050
The observed experimental behaviour of the studied compounds reveals that, for ornidazole and metronidazole, the rate of electron transfer becomes the determinant of overall sequential association via electron transfer controlled hydrogen bonding step, as ET is significantly slower in ratecomparedtothatofthebinding process. The effect determining the value of kO/R s is likely due to a competing intramolecular bond formation, which affords amorestableinitialstructureofthecompoundtobereduced. In terms of electrochemical reactions, the voltammograms become irreversible and the shifts in peak potentials can be employed to evaluate both the ET rate, along with the binding constant KB of the studied systems. This methodology will be used in further studies considering association with other types of molecules in which conformational changes could occur associated with ET.
2. Dextrin cross linked with poly(HEMA): a novel hydrogel for colon specific delivery of ornidazole
Dipankar Das, Raghunath Das, Paulomi Ghosh, Santanu Dhara, Asit Baran Pandac and Sagar Pal*. RSC Adv., 2013, 3, 25340–25350
Further, several antibiotics, such as ciprooxacin, metronidazole, ornidazole, tetracycline hydrochloride have been used for treatment of colon related disorders. Out of these ornidazole is the preferred drug,mostly used in the treatment of severe hepatic and intestinal amoebiasis, as it has antiprotozoal and antibacterial properties against anaerobic bacteria. It is used in the treatment and prophylaxis of susceptible anaerobic infections in gastric surgery. However, due to the complete and prompt absorption after oral administration and short biological half life of ornidazole, it is essential to deliver the drug in a more sustained way to provide longer bioavailability and hence its administration in tablet form may provide aminimumamount of ornidazole for local action in the colon. In spite of the development of various drug delivery systems, like carboxymethyl chitosan hydrogel, hydrogel based on sterculia gum–polyHEMA–polyacrylic acid, hydrogel derived from sterculia gum and poly(vinyl pyrrolidone), HPMC, and ethyl cellulose, to investigate the colon specific release behaviour of ornidazole, it is essential to develop new colon specific delivery systems for ornidazole to overcome important shortcomings of developed hydrogels, like specificity, biodegradability, biocompatibility, drug stability, and most importantly controlled release properties.
3. A study on the formation of the nitro radical anion by ornidazole and its significant decrease in a structurally characterized binuclear Cu(II)-complex: impact in biology
Ramesh Chandra Santra, Durba Ganguly, Jyotsna Singh, Kasturi Mukhopadhyay and Saurabh Das*. Dalton Trans.,2015, 44,1992–2000
A Cu(II) complex of ornidazole was prepared and characterized. Using Onz and the complex, we showed that the complex was able to drastically decrease the formation of the nitro-radical anion in an enzyme assay where hypoxanthine reduces the nitro group in the presence of xanthine oxidase. DNA binding experiments with Onz and the complex revealed no improvement in binding in favor of the complex. However, the efficacy of the complex remained unaltered towards bacterial cells Staphylococcus aureus and Escherichia coli. Formation of the nitro radical anion is responsible for antiparasitic/antibacterial activity as well as toxic side effects to the central nervous system, and it appears from this study that even with decreased nitro radical anions, the complexes are quite active. This study therefore suggests that complex formation strikes the correct balance for the generation of nitro radical anion that is able to maintain efficacy on bacterial cells, leaving no excess for toxic side effects.
4. Modified biopolymer-dextrin based crosslinked hydrogels: application in controlled drug delivery
Dipankar Das and Sagar Pal*. RSC Adv.,2015, 5,25014–25050
Also, the presence of poly(HEMA) as well MBA in the hydrogel structure enhanced the hydrophilicity of the network, which offers more functional groups as well as a higher surface area. This provides the release of the enclosed drug in a more sustained way. It was also pointed out that the interaction between the hydrogel and ornidazole is mainly a physical interaction, as shown in Fig. 21a. The in vitro release of ornidazole from the hydrogel followed a first order kinetic and non-Fickian diffusion mechanism. The drug stability study confirmed that ~98% of the ornidazole remains stable in the hydrogel for up to 3 months. The dextrin and poly(HEMA) based hydrogel also showed excellent release characteristics for the antibiotic ciprofloxacin (33.75% release after 18 h) (Fig. 24b). It was also observed through various characterizations that physical interactions mainly predominate between ciprofloxacin and the hydrogel in the tablet formulation (Fig. 21b). In addition, c-Dxt/pHEMA demonstrated excellent potential as ciprofloxacin carrier for up to 3 months, as ~98.5% of the drug was stable.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Antibacterial Products

CAS 34444-01-4 Cefamandole

(CAS: 34444-01-4)

Cefamandole is is the formate ester cefamandole nafate, a second-generation broad-spectrum cephalosporin antibiotic. It releases free NMTT, which can cause hypo...

CAS 6004-24-6 Hexadecylpyridinium chloride monohydrate

Hexadecylpyridinium chloride monohydrate
(CAS: 6004-24-6)

Hexadecylpyridinium chloride monohydrate is a broad antimicrobial spectrum with a rapid bactericidal effect on gram-positive pathogens and a fungicide effect on...

CAS 61379-65-5 Rifapentine

(CAS: 61379-65-5)

Rifapentine (Priftin) is an semi-synthetic antibiotic compound used in the treatment of tuberculosis.

CAS 7081-44-9 Cloxacillin Sodium

Cloxacillin Sodium
(CAS: 7081-44-9)

Cloxacillin Sodium is a sodium salt of cloxacillin that is a penicillinase-resistant, acid resistant, semi-synthetic penicillin.

CAS 252260-02-9 Posizolid

(CAS: 252260-02-9)

Posizolid is an oxazolidinone antibiotic that had been in phase II clinical trials for the treatment of tuberculosis but was discontinued.


LAH4, a-helix of the amphipathic peptide antibiotic, strongly interacts with phospholipid membranes, exhibiting in vitro transfection efficiency. The LAH4 famil...

CAS 115551-26-3 Marbofloxacin hydrochloride

Marbofloxacin hydrochloride
(CAS: 115551-26-3)

Marbofloxacin hydrochloride is a potent antibiotic by inhibiting DNA-gyrase.

(CAS: 194928-82-0)

FR-193879, a cephem derivative, is an efficacious anti-Helicobacter pylori cephalosporin.

CAS 131-69-1 Phthalylsulfacetamide

(CAS: 131-69-1)

Phthalylsulfacetamide, a sulfanilamide derivative, is a predrug of sulfacetamide and could be used as an antibacterial agent.

CAS 73384-59-5 Ceftriaxone

(CAS: 73384-59-5)

Ceftriaxone is an antibiotic useful for the treatment of a number of bacterial infections. It inhibits bacterial cell wall synthesis by means of binding to the ...

(CAS: 1381289-58-2)

Ribocil, a newly developed riboswitches chemical modulator, could selectively restrain the expression of GFP and probably influence bacterial cell growth. IC50:...

Norvancomycin hydrochloride
(CAS: 213997-73-0)

Norvancomycin hydrochloride is an antibacterial agent.

CAS 141702-36-5 Faropenem daloxate

Faropenem daloxate
(CAS: 141702-36-5)

Faropenem daloxate is useful for penem and antibiotics. Faropenem medoxomil has excellent in vitro activity against Streptococcus pneumoniae, Haemophilus influe...

CAS 100929-99-5 PAβN dihydrochloride

PAβN dihydrochloride
(CAS: 100929-99-5)

PAβN dihydrochloride, also known as MC-207110 dihydrochloride, is a broad-spectrum efflux pump inhibitor in Pseudomonas aeruginosa.

CAS 116-43-8 Succinylsulfathiazole

(CAS: 116-43-8)

Succinylsulfathiazole, a sulfonamide derivative, could restrain the bacteria in the intestine to block the production of folic acid.

CAS 526-08-9 Sulfaphenazole

(CAS: 526-08-9)

Sulfaphenazole is an inhibitor of CYP2C9 (Ki = 0.3 μM) acts as an antibacterial and antimicrobial.

CAS 69-53-4 Ampicillin

(CAS: 69-53-4)

Ampicillin is a beta-lactam antibiotic that is part of the aminopenicillin family and is roughly equivalent to its successor, amoxicillin in terms of spectrum a...

CAS 223652-90-2 Garenoxacin Mesylate hydrate

Garenoxacin Mesylate hydrate
(CAS: 223652-90-2)

Garenoxacin Mesylate hydrate is the Mesylate hydrate salt form of Garenoxacin. Garenoxacin, also called as BMS 284756, a new desfluoro(6)quinolone, is a topoiso...

CAS 122841-10-5 Cefoselis

(CAS: 122841-10-5)

Cefoselis, a new parenteral cephalosporin, was active against clinical isolates of both gram-positive and gram-negative aerobic bacteria. The activity of Cefose...

CP 99433
(CAS: 147059-71-0)

CP 99433, a fluoroquinolone derivative, has been found to be a Type II DNA topoisomerase inhibitor that could be probably effective as an antibacterial agent.

Chemical Structure

CAS 16773-42-5 Ornidazole

Quick Inquiry

Verification code

Featured Items